Literature DB >> 33558524

Germline mutational spectrum in Armenian breast cancer patients suspected of hereditary breast and ovarian cancer.

Mike M Moradian1,2, Davit T Babikyan3,4, Sione Markarian5, Jonny G Petrosyan4, Nare Avanesian5, Tereza Arutunyan5, Tamara F Sarkisian3,4.   

Abstract

Hereditary breast and ovarian cancer (HBOC) can be identified by genetic testing of cancer-causing genes. In this study, we identified a spectrum of genetic variations among 76 individuals of Armenian descent either with a family history of cancer or breast cancer before the age of 40. We screened 76 suspected HBOC patients and family members as well as four healthy controls using a targeted and hereditary comprehensive cancer panel (127 genes). We found 26 pathogenic (path) and 6 likely pathogenic (LPath)variants in 6 genes in 44 patients (58%); these variants were found in BRCA1 (17), BRCA2 (19), CHEK2 (4), PALB2 (2), and NBN (1). A few different variants were found in unrelated individuals; most notably, variant p.Trp1815Ter in the BRCA1 gene occurred in four unrelated patients. We did not find any known significant variants in five patients. Comprehensive cancer panel testing revealed pathogenic variants in cancer genes other than BRCA1 and BRCA2, suggesting that testing only BRCA1 and BRCA2 would have missed 8 out of 44 suspected HBOC patients (18%). These data also confirm that a comprehensive cancer panel testing approach could be an appropriate way to identify most of the variants associated with hereditary breast cancer.

Entities:  

Year:  2021        PMID: 33558524      PMCID: PMC7870655          DOI: 10.1038/s41439-021-00140-2

Source DB:  PubMed          Journal:  Hum Genome Var        ISSN: 2054-345X


  22 in total

1.  SIFT missense predictions for genomes.

Authors:  Robert Vaser; Swarnaseetha Adusumalli; Sim Ngak Leng; Mile Sikic; Pauline C Ng
Journal:  Nat Protoc       Date:  2015-12-03       Impact factor: 13.491

2.  Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.

Authors:  Daphne W Bell; Sang H Kim; Andrew K Godwin; Taryn A Schiripo; Patricia L Harris; Sara M Haserlat; Doke C R Wahrer; Christopher A Haiman; Mary B Daly; Kristin B Niendorf; Matthew R Smith; Dennis C Sgroi; Judy E Garber; Olufunmilayo I Olopade; Loic Le Marchand; Brian E Henderson; David Altshuler; Daniel A Haber; Matthew L Freedman
Journal:  Int J Cancer       Date:  2007-12-15       Impact factor: 7.396

3.  Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study.

Authors:  Ake Borg; Robert W Haile; Kathleen E Malone; Marinela Capanu; Ahn Diep; Therese Törngren; Sharon Teraoka; Colin B Begg; Duncan C Thomas; Patrick Concannon; Lene Mellemkjaer; Leslie Bernstein; Lina Tellhed; Shanyan Xue; Eric R Olson; Xiaolin Liang; Jessica Dolle; Anne-Lise Børresen-Dale; Jonine L Bernstein
Journal:  Hum Mutat       Date:  2010-03       Impact factor: 4.878

4.  Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil.

Authors:  Crisle Vignol Dillenburg; Isabel Cristina Bandeira; Taiana Valente Tubino; Luciana Grazziotin Rossato; Eleonora Souza Dias; Ana Cristina Bittelbrunn; Sandra Leistner-Segal
Journal:  Genet Mol Biol       Date:  2012-08-17       Impact factor: 1.771

5.  Mutations of the SLX4 gene in Fanconi anemia.

Authors:  Yonghwan Kim; Francis P Lach; Rohini Desetty; Helmut Hanenberg; Arleen D Auerbach; Agata Smogorzewska
Journal:  Nat Genet       Date:  2011-01-16       Impact factor: 38.330

6.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

7.  Localization-dependent and -independent roles of SLX4 in regulating telomeres.

Authors:  Jamie S J Wilson; Agueda M Tejera; Dennis Castor; Rachel Toth; Maria A Blasco; John Rouse
Journal:  Cell Rep       Date:  2013-08-29       Impact factor: 9.423

8.  Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.

Authors:  Mary Pritzlaff; Pia Summerour; Rachel McFarland; Shuwei Li; Patrick Reineke; Jill S Dolinsky; David E Goldgar; Hermela Shimelis; Fergus J Couch; Elizabeth C Chao; Holly LaDuca
Journal:  Breast Cancer Res Treat       Date:  2016-12-22       Impact factor: 4.872

9.  Characterization of BRCA1/2 mutations in patients with family history of breast cancer in Armenia.

Authors:  Sofi Atshemyan; Andranik Chavushyan; Nerses Berberian; Arthur Sahakyan; Roksana Zakharyan; Arsen Arakelyan
Journal:  F1000Res       Date:  2017-01-10

10.  CADD: predicting the deleteriousness of variants throughout the human genome.

Authors:  Philipp Rentzsch; Daniela Witten; Gregory M Cooper; Jay Shendure; Martin Kircher
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

View more
  1 in total

1.  Germline Testing in a Cohort of Patients at High Risk of Hereditary Cancer Predisposition Syndromes: First Two-Year Results from South Italy.

Authors:  Francesco Paduano; Emma Colao; Fernanda Fabiani; Valentina Rocca; Francesca Dinatolo; Adele Dattola; Lucia D'Antona; Rosario Amato; Francesco Trapasso; Francesco Baudi; Nicola Perrotti; Rodolfo Iuliano
Journal:  Genes (Basel)       Date:  2022-07-21       Impact factor: 4.141

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.